Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells.

International Journal of Cancer. Journal International Du Cancer
H Ashino-FuseT Iwaguchi

Abstract

Medroxyprogesterone acetate (MPA) is an anti-cancer drug for mammary carcinomas and an angiostatic steroid. The effects of MPA on the growth and plasminogen activator (PA) activity of bovine endothelial cells were investigated to elucidate the inhibitory mechanism observed in angiogenesis. MPA did not suppress the growth of capillary endothelial cells, even at high concentrations. On the other hand, in bovine endothelial cells of 3 types (adrenal cortical capillary, aortic and pulmonary artery endothelial cells), MPA inhibited extracellular and cell-associated activity of PA, which might be a protease involved in the neovascular response. MPA also greatly inhibited the high level of PA induced by basic fibroblast growth factor (FGF). The same result was obtained when PA production was induced by 4 beta-phorbol-12-myristate-13-acetate (PMA) in endothelial cells. These findings suggest that one of the points of inhibitory action of MPA in the process of angiogenesis may be the suppression of PA activity, and that inhibition of this protease might be useful for reduction of tumorigenic or excessive angiogenesis in vivo.

References

Dec 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·S C Seifert, T D Gelehrter
May 1, 1975·The Journal of Experimental Medicine·Y A Sidky, R Auerbach
Oct 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·J FolkmanB R Zetter
Jan 22, 1976·Nature·M Wigler, I B Weinstein
Oct 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·R MontesanoL Orci
Oct 1, 1986·Seminars in Thrombosis and Hemostasis·R H GoldfarbL A Liotta
Feb 1, 1987·Journal of Cellular Physiology·R Montesano, L Orci
Jan 1, 1985·Advances in Cancer Research·K DanøL Skriver
Sep 1, 1986·European Journal of Cancer & Clinical Oncology·A JakobsenM Kjaer
Apr 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·D MoscatelliD B Rifkin
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J P QuigleyL M Sullivan
Oct 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·R Mira-y-LopezL Ossowski
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D MoscatelliD B Rifkin
Apr 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·P A Barouski-Miller, T D Gelehrter
Feb 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·J GrossJ Folkman
May 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·J L GrossD B Rifkin
Jun 1, 1984·Proceedings of the Society for Experimental Biology and Medicine·H Ashino-FuseA Billiau

❮ Previous
Next ❯

Citations

Feb 1, 1994·Journal of Cellular Physiology·J LaterraG W Goldstein
Jul 1, 1992·European Journal of Pediatrics·L Schweigerer, T Fotsis
Nov 25, 2000·Breast Cancer : the Journal of the Japanese Breast Cancer Society·H Koyama
Sep 14, 1993·European Journal of Pharmacology·T OikawaS Murota
Sep 1, 1994·Pharmacology & Therapeutics·W Auerbach, R Auerbach
Jan 14, 2003·European Journal of Pharmacology·Kazumasa AokiTsutomu Oikawa
Dec 28, 1999·European Journal of Pharmacology·M NakamuraT Oikawa
Jul 1, 1997·Cancer Treatment Reviews·A P Jekunen, K J Kairemo
Aug 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R NishimuraK Ikeda
Oct 26, 1999·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·L G McNattA F Clark
Sep 1, 1995·Obstetrical & Gynecological Survey·J D GordonR B Jaffe
Dec 19, 2015·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Fumitaka SaitoHidetaka Katabuchi
Jul 2, 2005·Expert Opinion on Investigational Drugs·A F Clark
Jul 1, 1992·American Journal of Obstetrics and Gynecology·H JikiharaN Terakawa
Sep 6, 1994·Annals of the New York Academy of Sciences·E P SiposH Brem
Feb 1, 1994·International Journal of Cancer. Journal International Du Cancer·T YamamotoV Petrow
Jan 5, 2006·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Peter J Kertes, Stuart G Coupland
Feb 18, 1999·Gynecologic Oncology·O AbulafiaD M Sherer
Jan 1, 1992·Japanese Journal of Cancer Research : Gann·T OikawaM Shimamura
May 26, 1998·Biochemical and Biophysical Research Communications·T OikawaK Tanaka

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.